Stock BJ9 BENITEC BIOPHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Benitec Biopharma Inc. Deutsche Boerse AG

Equities

BJ9

US08205P2092

Biotechnology & Medical Research

Delayed Deutsche Boerse AG
Other stock markets
 07:11:42 25/07/2023 BST 		5-day change 1st Jan Change
3.06 EUR -2.70% Intraday chart for Benitec Biopharma Inc. -.--% -.--%
05-13 Benitec Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 CI
04-22 Benitec Biopharma Inc. announced that it has received $40.000019 million in funding from a group of investors CI

Valuation

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 14.64 12.28 44.52 13.74 10.02 107.9 - -
Enterprise Value (EV) 1 14.64 12.28 44.52 13.74 10.02 107.9 107.9 107.9
P/E ratio 67.1 x -1.01 x -1.27 x -0.52 x -0.28 x -3.03 x -8.56 x -
Yield - - - - - - - -
Capitalization / Revenue 0.84 x 86.5 x - 128 x 86.9 x - - -
EV / Revenue 0.84 x 86.5 x - 128 x 86.9 x - - -
EV / EBITDA - - - -531,615 x - - - -
EV / FCF - - - -0.59 x - -3.34 x -2.52 x 4.67 x
FCF Yield - - - -169% - -29.9% -39.6% 21.4%
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 857 63 462 481 1,646 9,367 - -
Reference price 2 272.1 194.9 96.37 28.59 6.088 11.52 11.52 11.52
Announcement Date 29/08/19 06/10/20 20/09/21 02/09/22 21/09/23 - - -
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 17.51 0.142 - 0.1077 0.1153 - - -
EBITDA - - - -25.85 - - - -
EBIT 1 - -10.14 - -26.35 -29.34 -44.53 -68.45 -40.8
Operating Margin - -7,138.43% - -24,458.3% -25,441.88% - - -
Earnings before Tax (EBT) - - - -26.87 - - - -
Net income - - -19.13 -26.87 - - - -
Net margin - - - -24,943.26% - - - -
EPS 2 4.054 -192.4 -75.65 -55.41 -21.72 -3.800 -1.346 -
Free Cash Flow 1 - - - -23.26 - -32.27 -42.77 23.1
FCF margin - - - -21,589.69% - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 29/08/19 06/10/20 20/09/21 02/09/22 21/09/23 - - -
1AUD in Million2AUD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: June 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3 2025 Q4
Net sales 1 - 0.0694 - - 0.0202 0.0812 0.0108 - - - - - - - -
EBITDA - -4.921 -6.917 -6.9 - - - - - - - - - - -
EBIT - -5.001 -6.992 -6.963 - - - - - - - - - - -
Operating Margin - -7,208.79% - - - - - - - - - - - - -
Earnings before Tax (EBT) - -4.733 -7.478 -7.743 - - - - - - - - - - -
Net income -6.769 -4.733 -7.478 -7.743 - - - - - - - - - - -
Net margin - -6,823.35% - - - - - - - - - - - - -
EPS 2 -14.08 -9.824 -15.41 -12.15 -4.884 -4.063 - -4.345 -4.039 -2.484 -0.4640 -0.2840 -0.2990 -0.3590 -0.4190
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 14/02/22 16/05/22 02/09/22 10/11/22 13/02/23 15/05/23 21/09/23 13/11/23 13/02/24 13/05/24 - - - - -
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - - - -23.3 - -32.3 -42.8 23.1
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex 1 - - - 0.02 - 0.27 0.7 1.06
Capex / Sales - - - 17.64% - - - -
Announcement Date 29/08/19 06/10/20 20/09/21 02/09/22 21/09/23 - - -
1AUD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
11.52 AUD
Average target price
23.94 AUD
Spread / Average Target
+107.75%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+43.36% 54.63B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 39.92B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.86B
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.78B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12.21B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.16B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.94B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-11.83% 10.74B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. BNTC Stock
  4. BJ9 Stock
  5. Financials Benitec Biopharma Inc.